Abstract
The safety, immunogenicity, and immunologic priming of 2 dosages (2 μg or 10 μg) of a meningococcal C oligosaccharide-CRM197 conjugate vaccine was evaluated in 114 infants vaccinated at ages 2, 3, and 4 months. Antibody persistence and response to boosting with 10 μg of meningococcal C polysaccharide were assessed. The meningococcal conjugate vaccine produced fewer local reactions than concurrent routine immunizations. Total serogroup C-specific immunoglobulin geometric mean concentration (GMC) increased from 0.3 μg/mL before vaccination to 13.1 μg/mL at age 5 months. Serum bactericidal antibody (SBA) geometric mean titers (GMTs) rose from <1:4 to 1:1057 at 5 months and fell by 14 months to 1: 19. Following boosting, anti- C-specific immunoglobulin GMC rose to 15.9 μg/mL and SBA GMT to 1:495. Antibody responses in the 10-μg dose cohort were significantly higher at 5 months (P < .01) than in the 2-μg dose cohort but were lower after polysaccharide boosting (P = .02). This meningococcal conjugate vaccine was well tolerated and immunogenic and induced immunologic memory in infants.
| Original language | English |
|---|---|
| Pages (from-to) | 1569-1572 |
| Number of pages | 4 |
| Journal | Journal of Infectious Diseases |
| Volume | 179 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1999 |
Bibliographical note
Funding Information:Received 24 July 1998; revised 25 January 1999. Presented in part: Eleventh International Pathogenic Neisseria Conference, Nice, France, 1–6 November 1998 (abstract 72). Written informed consent was obtained from the parents or guardians of all study subjects, and the study protocol was approved by the west Gloucestershire local research ethics committee. Financial support: UK Department of Health (grant 121/369); Wyeth Lederle Vaccines and Pediatrics. Reprints or correspondence: Dr. Peter Richmond, ImmunisationDivision, PHLS Communicable Disease Surveillance Centre, 61 Colindale Ave., London NW9 5EQ, UK ([email protected]).
